endosergЭндокринная хирургияEndocrine Surgery2306-35132310-3965Типография «Печатных дел Мастер»10.14341/serg12712endoserg-12712Research ArticleНациональные клинические рекомендацииNational clinical recomendationsПроект клинических рекомендаций «Инциденталома надпочечника»Draft of the clinical practice guidelines “Adrenal incidentaloma”https://orcid.org/0000-0001-7098-4584БельцевичД. Г.BeltsevichD. G.

Бельцевич Дмитрий Германович, д.м.н., профессор, eLibrary SPIN: 4475-6327

Dmitriy G. Beltsevich, MD, PhD, Professor, eLibrary SPIN: 4475-6327

belts67@gmail.comhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

Трошина Екатерина Анатольевна, д.м.н., профессор, член-корреспондент РАН, eLibrary SPIN: 8821-8990

Ekaterina A. Troshina, MD, PhD, professor, eLibrary SPIN: 8821-8990

troshina@inbox.ruhttps://orcid.org/0000-0002-5634-7877МельниченкоГ. А.MelnichenkoG. A.

Мельниченко Галина Афанасьевна, д.м.н., профессор, академик РАН, eLibrary SPIN: 8615-0038

Galina A. Melnichenko, MD, PhD, Professor, eLibrary SPIN: 8615-0038

teofrast2000@mail.ruhttps://orcid.org/0000-0001-6388-1544ПлатоноваН. М.PlatonovaN. M.

Платонова Надежда Михайловна, д.м.н., eLibrary SPIN: 4053-3033

Nadezhda M. Platonova, MD, ScD, eLibrary SPIN: 4053-3033

doc-platonova@inbox.ruhttps://orcid.org/0000-0001-6418-7060ЛадыгинаД. О.LadyginaD. O.

Ладыгина Дарья Олеговна, к.м.н., eLibrary SPIN: 7958-9435

Daria O. Ladygina, MD, PhD, eLibrary SPIN: 7958-9435

ladygina.do@gmail.comhttps://orcid.org/0000-0001-5592-4794ШевэА.ChevaisA.

Шевэ Анастасия, аспирант, Россия, 117036, Москва, ул. Дм. Ульянова, д. 11, тел.: +7-962-993-27-63, eLibrary SPIN: 2459-0540

Anastassia Chevais, postgraduate student, 11 Dmitry Ulyanova street, 117036 Moscow, Russia, eLibrary SPIN: 2459-0540

anastassia93@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202127092021151426Copyright © Бельцевич Д.Г., Трошина Е.А., Мельниченко Г.А., Платонова Н.М., Ладыгина Д.О., Шевэ А., 20212021Бельцевич Д.Г., Трошина Е.А., Мельниченко Г.А., Платонова Н.М., Ладыгина Д.О., Шевэ А.Beltsevich D.G., Troshina E.A., Melnichenko G.A., Platonova N.M., Ladygina D.O., Chevais A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surg-endojournals.ru/jour/article/view/12712

Более широкое применение и техническое совершенствование процедур визуализации брюшной полости в последние годы привело к все более частому обнаружению образований надпочечников — инциденталом, требующих, в свою очередь, исключения гормональной активности и злокачественности.

Клинические рекомендации — это основной рабочий инструмент практикующего врача, как специалиста, так и врача узкой практики. Лаконичность, структурированность сведений об определенной нозологии, методов ее диагностики и лечения, базирующихся на принципах доказательной медицины, позволяют в короткий срок дать тот или иной ответ на интересующий вопрос специалисту, добиваться максимальной эффективности и персонализации лечения. Эти клинические рекомендации включают в себя данные о распространенности, этиологии, рентгенологических особенностях и оценке гормонального статуса инцидиенталом надпочечников. Кроме того, настоящие клинические рекомендации содержат информацию о показаниях к хирургическому лечению, послеоперационной реабилитации и последующем наблюдении.

The wider application and technical improvement of abdominal imaging procedures in recent years has led to an increasingly frequent detection of adrenal gland masses — adrenal incidentaloma, which have become a common clinical problem and need to be investigated for evidence of hormonal hypersecretion and/or malignancy. Clinical guidelines are the main working tool of a practicing physician. Laconic, structured information about a specific nosology, methods of its diagnosis and treatment, based on the principles of evidence-based medicine, make it possible to give answers to questions in a short time, to achieve maximum efficiency and personalization of treatment. These clinical guidelines include data on the prevalence, etiology, radiological features and assessment of hormonal status of adrenal incidentalomas. In addition, this clinical practice guideline provides information on indications for surgery, postoperative rehabilitation and follow-up.

надпочечникинциденталомаклинические рекомендацииadrenal glandincidentalomaguidelinesReferencesБельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников // Эндокринная хирургия. — 2009. — Т. 4. — №1. — С. 19–23. doi: https://doi.org/10.14341/2306-3513-2009-1-19-23Beltsevich DG, Kuznetsov NS, Soldatova TV, Vanushko VE. Adrenal incidentaloma. Endocrine Surgery. 2009;3(1):19-23. (In Russ.) doi: https://doi.org/10.14341/2306-3513-2009-1-19-23Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: https://doi.org/10.1530/EJE-16-0467Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: https://doi.org/10.1530/EJE-16-0467Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi: https://doi.org/10.1210/er.2002-0031Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi: https://doi.org/10.1210/er.2002-0031Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii131-vii138. doi: https://doi.org/10.1093/annonc/mds231Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii131-vii138. doi: https://doi.org/10.1093/annonc/mds231Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7(7):712-747. doi: https://doi.org/10.6004/jnccn.2009.0050Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7(7):712-747. doi: https://doi.org/10.6004/jnccn.2009.0050Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484. doi: https://doi.org/10.1210/edrv-16-4-460Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484. doi: https://doi.org/10.1210/edrv-16-4-460Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298-302. doi: https://doi.org/10.1007/BF03344099Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298-302. doi: https://doi.org/10.1007/BF03344099Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi: https://doi.org/10.1056/NEJMcp065470Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi: https://doi.org/10.1056/NEJMcp065470Cawood TJ, Hunt PJ, O’Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009;161(4):513-527. doi: https://doi.org/10.1530/EJE-09-0234Cawood TJ, Hunt PJ, O’Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009;161(4):513-527. doi: https://doi.org/10.1530/EJE-09-0234Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46. Published 2018 Oct 1. doi: https://doi.org/10.1530/EJE-18-0608Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46. Published 2018 Oct 1. doi: https://doi.org/10.1530/EJE-18-0608Ahmed AA, Thomas AJ, Ganeshan DM, et al. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). 2020;45(4):945-963. doi: https://doi.org/10.1007/s00261-019-02371-yAhmed AA, Thomas AJ, Ganeshan DM, et al. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). 2020;45(4):945-963. doi: https://doi.org/10.1007/s00261-019-02371-yGross MD, Shapiro B. Clinical review 50: Clinically silent adrenal masses. J Clin Endocrinol Metab. 1993;77(4):885-888. doi: https://doi.org/10.1210/jcem.77.4.8408461Gross MD, Shapiro B. Clinical review 50: Clinically silent adrenal masses. J Clin Endocrinol Metab. 1993;77(4):885-888. doi: https://doi.org/10.1210/jcem.77.4.8408461Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: https://doi.org/10.1530/EJE-10-1147Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: https://doi.org/10.1530/EJE-10-1147Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-x. doi: https://doi.org/10.1016/j.ecl.2005.01.008Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-x. doi: https://doi.org/10.1016/j.ecl.2005.01.008Terzolo M, Bovio S, Pia A, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005;153(2):307-315. doi: https://doi.org/10.1530/eje.1.01959Terzolo M, Bovio S, Pia A, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005;153(2):307-315. doi: https://doi.org/10.1530/eje.1.01959Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. doi: https://doi.org/10.1210/jc.2001-011766Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. doi: https://doi.org/10.1210/jc.2001-011766Morelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf ). 2010;73(2):161-166. doi: https://doi.org/10.1111/j.1365-2265.2010.03794.xMorelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf ). 2010;73(2):161-166. doi: https://doi.org/10.1111/j.1365-2265.2010.03794.xMantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644. doi: https://doi.org/10.1210/jcem.85.2.6372Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644. doi: https://doi.org/10.1210/jcem.85.2.6372Kirkby-Bott J, Brunaud L, Mathonet M, et al. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012;36(6):1382-1388. doi: https://doi.org/10.1007/s00268-012-1488-1Kirkby-Bott J, Brunaud L, Mathonet M, et al. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012;36(6):1382-1388. doi: https://doi.org/10.1007/s00268-012-1488-1Мельниченко Г.А., Алексеев Б.Я., Бельцевич Д.Г., и др. Клинические рекомендации. Рак коры надпочечников (адренокортикальный рак). 2020.Melnichenko GA, Aleskeev BY, Beltsevich DG, et al. Clinical practice guidelines. Adrenal cortex cancer (adrenocortical cancer). 2020. (In Russ.)Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi: https://doi.org/10.1210/jc.2015-1818Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi: https://doi.org/10.1210/jc.2015-1818Libè R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002;147(4):489-494. doi: https://doi.org/10.1530/eje.0.1470489Libè R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002;147(4):489-494. doi: https://doi.org/10.1530/eje.0.1470489Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;171(2):107-116. doi: https://doi.org/10.7326/M18-3630Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;171(2):107-116. doi: https://doi.org/10.7326/M18-3630Кузнецов Н.С., Бельцевич Д.Г., Ванушко В.Э., и др. Дифференциальная диагностика инциденталом надпочечников // Эндокринная хирургия. — 2011. — Т. 5. — №1. — С.5–16. doi: https://doi.org/10.14341/2306-3513-2011-1-5-16Kuznetsov NS, Beltsevich DG, Vanushko VE, et al. Differential diagnostics of adrenal incedentaloma. Endocrine Surgery. 2011;5(1):5-16. (In Russ.) doi: https://doi.org/10.14341/2306-3513-2011-1-5-16Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: https://doi.org/10.1210/jc.2008-0125Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: https://doi.org/10.1210/jc.2008-0125Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J Endocrinol Invest. 2017;40(7):753-760. doi: https://doi.org/10.1007/s40618-017-0644-8Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J Endocrinol Invest. 2017;40(7):753-760. doi: https://doi.org/10.1007/s40618-017-0644-8Penezić Z, Zarković M, Vujović S, et al. Value of assessing adrenocorticotropic hormone (ACTH) levels in differential diagnosis of hypercorticism. Med Pregl. 2004;57(7-8):335-342. doi: https://doi.org/10.2298/mpns0408335pPenezić Z, Zarković M, Vujović S, et al. Value of assessing adrenocorticotropic hormone (ACTH) levels in differential diagnosis of hypercorticism. Med Pregl. 2004;57(7-8):335-342. doi: https://doi.org/10.2298/mpns0408335pOlsen H, Kjellbom A, Löndahl M, Lindgren O. Suppressed ACTH Is Frequently Unrelated to Autonomous Cortisol Secretion in Patients With Adrenal Incidentalomas. J Clin Endocrinol Metab. 2019;104(2):506-512. doi: https://doi.org/10.1210/jc.2018-01029Olsen H, Kjellbom A, Löndahl M, Lindgren O. Suppressed ACTH Is Frequently Unrelated to Autonomous Cortisol Secretion in Patients With Adrenal Incidentalomas. J Clin Endocrinol Metab. 2019;104(2):506-512. doi: https://doi.org/10.1210/jc.2018-01029Di Dalmazi G, Berr CM, Fassnacht M, et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J Clin Endocrinol Metab. 2014;99(8):2637-2645. doi: https://doi.org/10.1210/jc.2014-1401Di Dalmazi G, Berr CM, Fassnacht M, et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J Clin Endocrinol Metab. 2014;99(8):2637-2645. doi: https://doi.org/10.1210/jc.2014-1401Prete A, Paragliola RM, Bottiglieri F, et al. Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome. Endocrine. 2017;55(3):969-980. doi: https://doi.org/10.1007/s12020-016-1007-5Prete A, Paragliola RM, Bottiglieri F, et al. Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome. Endocrine. 2017;55(3):969-980. doi: https://doi.org/10.1007/s12020-016-1007-5Hurtado MD, Cortes T, Natt N, et al. Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess. Clin Endocrinol (Oxf ). 2018;89(6):721-733. doi: https://doi.org/10.1111/cen.13803Hurtado MD, Cortes T, Natt N, et al. Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess. Clin Endocrinol (Oxf ). 2018;89(6):721-733. doi: https://doi.org/10.1111/cen.13803Schalin-Jäntti C, Raade M, Hämäläinen E, Sane T. A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion. Endocrinol Metab (Seoul). 2015;30(4):481-487. doi: https://doi.org/10.3803/EnM.2015.30.4.481Schalin-Jäntti C, Raade M, Hämäläinen E, Sane T. A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion. Endocrinol Metab (Seoul). 2015;30(4):481-487. doi: https://doi.org/10.3803/EnM.2015.30.4.481Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: https://doi.org/10.1210/jc.2014-1498Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: https://doi.org/10.1210/jc.2014-1498Därr R, Kuhn M, Bode C, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56(3):495-503. doi: https://doi.org/10.1007/s12020-017-1300-yDärr R, Kuhn M, Bode C, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56(3):495-503. doi: https://doi.org/10.1007/s12020-017-1300-yMullins F, O’Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2011;50(1):105-110. Published 2011 Oct 8. doi: https://doi.org/10.1515/CCLM.2011.742Mullins F, O’Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2011;50(1):105-110. Published 2011 Oct 8. doi: https://doi.org/10.1515/CCLM.2011.742Мельниченко Г.А., Трошина Е.А., Бельцевич Д.Г., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению феохромоцитомы/параганглиомы // Эндокринная хирургия. — 2015. — Т. 9. — №3. — С. 15–33. doi: https://doi.org/10.14341/serg2015315-33Melnichenko GA, Troshina EA, Beltsevich DG, et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33. (In Russ.)]. doi: https://doi.org/10.14341/serg2015315-33Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434. doi: https://doi.org/10.1001/jama.287.11.1427Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434. doi: https://doi.org/10.1001/jama.287.11.1427Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346. doi: https://doi.org/10.1016/j.beem.2019.101346Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346. doi: https://doi.org/10.1016/j.beem.2019.101346Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577-585. doi: https://doi.org/10.1055/s-0029-1237699Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577-585. doi: https://doi.org/10.1055/s-0029-1237699Neary NM, King KS, Pacak K. Drugs and pheochromocytoma--don’t be fooled by every elevated metanephrine. N Engl J Med. 2011;364(23):2268-2270. doi: https://doi.org/10.1056/NEJMc1101502#SA1Neary NM, King KS, Pacak K. Drugs and pheochromocytoma--don’t be fooled by every elevated metanephrine. N Engl J Med. 2011;364(23):2268-2270. doi: https://doi.org/10.1056/NEJMc1101502#SA1Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from falsepositive test results. J Clin Endocrinol Metab. 2003;88(6):2656-2666. doi: https://doi.org/10.1210/jc.2002-030005Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from falsepositive test results. J Clin Endocrinol Metab. 2003;88(6):2656-2666. doi: https://doi.org/10.1210/jc.2002-030005Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17(2):392-400. doi: https://doi.org/10.1245/s10434-009-0850-5Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17(2):392-400. doi: https://doi.org/10.1245/s10434-009-0850-5Derlin T, Busch JD, Wisotzki C, et al. Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med. 2013;38(1):e1-e6. doi: https://doi.org/10.1097/RLU.0b013e318263923dDerlin T, Busch JD, Wisotzki C, et al. Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med. 2013;38(1):e1-e6. doi: https://doi.org/10.1097/RLU.0b013e318263923dSane T, Schalin-Jäntti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?. J Clin Endocrinol Metab. 2012;97(6):2077-2083. doi: https://doi.org/10.1210/jc.2012-1061Sane T, Schalin-Jäntti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?. J Clin Endocrinol Metab. 2012;97(6):2077-2083. doi: https://doi.org/10.1210/jc.2012-1061Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018;178(5):431-437. doi: https://doi.org/10.1530/EJE-18-0006Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018;178(5):431-437. doi: https://doi.org/10.1530/EJE-18-0006Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. doi: https://doi.org/10.1210/jc.2014-3663Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. doi: https://doi.org/10.1210/jc.2014-3663Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248. doi: https://doi.org/10.1016/j.jacc.2005.01.015Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248. doi: https://doi.org/10.1016/j.jacc.2005.01.015Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: https://doi.org/10.1111/joim.12831Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: https://doi.org/10.1111/joim.12831Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589-1593.Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589-1593.McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab. 1991;73(5):952-957. doi: https://doi.org/10.1210/jcem-73-5-952McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab. 1991;73(5):952-957. doi: https://doi.org/10.1210/jcem-73-5-952Stowasser M, Gordon RD. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1-2):33-39. doi: https://doi.org/10.1016/j.mce.2003.10.006Stowasser M, Gordon RD. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1-2):33-39. doi: https://doi.org/10.1016/j.mce.2003.10.006Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. J Clin Hypertens (Greenwich). 2021;23(2):201-207. doi: https://doi.org/10.1111/jch.14117Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. J Clin Hypertens (Greenwich). 2021;23(2):201-207. doi: https://doi.org/10.1111/jch.14117O’Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges. Int J Clin Pract. 2019;73(7):e13353. doi: https://doi.org/10.1111/ijcp.13353O’Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges. Int J Clin Pract. 2019;73(7):e13353. doi: https://doi.org/10.1111/ijcp.13353Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84-92. doi: https://doi.org/10.1055/a-0672-0836Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84-92. doi: https://doi.org/10.1055/a-0672-0836Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170-176. doi: https://doi.org/10.1055/s-0031-1295460Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170-176. doi: https://doi.org/10.1055/s-0031-1295460Widimský J, Bruthans J, Wohlfahrt P, et al. Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Press. 2020;29(3):191-198. doi: https://doi.org/10.1080/08037051.2020.1723406Widimský J, Bruthans J, Wohlfahrt P, et al. Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Press. 2020;29(3):191-198. doi: https://doi.org/10.1080/08037051.2020.1723406Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/ AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. Ann Endocrinol (Paris). 2016;77(3):192-201. doi: https://doi.org/10.1016/j.ando.2016.02.003Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/ AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. Ann Endocrinol (Paris). 2016;77(3):192-201. doi: https://doi.org/10.1016/j.ando.2016.02.003Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf ). 2007;66(5):607-618. doi: https://doi.org/10.1111/j.1365-2265.2007.02775.xYoung WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf ). 2007;66(5):607-618. doi: https://doi.org/10.1111/j.1365-2265.2007.02775.xMosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165. doi: https://doi.org/10.1161/01.HYP.0000079505.25750.11Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165. doi: https://doi.org/10.1161/01.HYP.0000079505.25750.11Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: https://doi.org/10.1210/jc.2015-4061Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: https://doi.org/10.1210/jc.2015-4061Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045-1050. doi: https://doi.org/10.1210/jc.2003-031337Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045-1050. doi: https://doi.org/10.1210/jc.2003-031337Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-1820. doi: https://doi.org/10.1016/j.jacc.2017.01.052Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-1820. doi: https://doi.org/10.1016/j.jacc.2017.01.052Kokko E, Nevalainen PI, Choudhary MK, et al. Aldosteroneto-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. Sci Rep. 2020;10(1):19804. Published 2020 Nov 13. doi: https://doi.org/10.1038/s41598-020-76718-7Kokko E, Nevalainen PI, Choudhary MK, et al. Aldosteroneto-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. Sci Rep. 2020;10(1):19804. Published 2020 Nov 13. doi: https://doi.org/10.1038/s41598-020-76718-7Kisaka T, Ozono R, Ishida T, et al. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012;30(12):2322-2330. doi:10.1097/HJH.0b013e328359862dKisaka T, Ozono R, Ishida T, et al. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012;30(12):2322-2330. doi:10.1097/HJH.0b013e328359862dShapiro Y, Boaz M, Matas Z, et al. The association between the renin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects. Clin Endocrinol (Oxf ). 2008;68(4):510-512. doi: https://doi.org/10.1111/j.1365-2265.2008.03176.xShapiro Y, Boaz M, Matas Z, et al. The association between the renin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects. Clin Endocrinol (Oxf ). 2008;68(4):510-512. doi: https://doi.org/10.1111/j.1365-2265.2008.03176.xCain JP, Tuck ML, Williams GH, et al. The regulation of aldosterone secretion in primary aldosteronism. Am J Med. 1972;53(5):627-637. doi: https://doi.org/10.1016/0002-9343(72)90158-1Cain JP, Tuck ML, Williams GH, et al. The regulation of aldosterone secretion in primary aldosteronism. Am J Med. 1972;53(5):627-637. doi: https://doi.org/10.1016/0002-9343(72)90158-1d’Alva CB, Abiven-Lepage G, Viallon V, et al. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess. Eur J Endocrinol. 2008;159(5):641-647. doi: https://doi.org/10.1530/EJE-08-0324d’Alva CB, Abiven-Lepage G, Viallon V, et al. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess. Eur J Endocrinol. 2008;159(5):641-647. doi: https://doi.org/10.1530/EJE-08-0324Di Dalmazi G. Hyperandrogenism and Adrenocortical Tumors. Front Horm Res. 2019;53:92-99. doi: https://doi.org/10.1159/000494905Di Dalmazi G. Hyperandrogenism and Adrenocortical Tumors. Front Horm Res. 2019;53:92-99. doi: https://doi.org/10.1159/000494905Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-4564. doi: https://doi.org/10.1210/jc.2013-3020Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-4564. doi: https://doi.org/10.1210/jc.2013-3020Chortis V, Bancos I, Nijman T, et al. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2020;105(3):e307-e318. doi: https://doi.org/10.1210/clinem/dgz141Chortis V, Bancos I, Nijman T, et al. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2020;105(3):e307-e318. doi: https://doi.org/10.1210/clinem/dgz141Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2009;2009:624823. doi: https://doi.org/10.1155/2009/624823Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2009;2009:624823. doi: https://doi.org/10.1155/2009/624823Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol. 2018;179(2):R57-R67. doi: https://doi.org/10.1530/EJE-18-0296Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol. 2018;179(2):R57-R67. doi: https://doi.org/10.1530/EJE-18-0296Шевэ А., Селиванова Л.С., Кузнецов Н.С., и др. Иммуногистохимическое исследование экспрессии аберрантных/эутопических рецепторов у пациентов с макронодулярной гиперплазией надпочечников // Проблемы эндокринологии. — 2020. — Т. 66. — №6. — С. 4-12. doi: https://doi.org/10.14341/probl12516Chevais A, Selivanova LS, Kuznetsov NS, et al. Immunohistochemical study on the expression/hyperexpression of aberrant/eutopic receptors in patients with bilateral macronodular adrenal hyperplasia. Problems of Endocrinology. 2020;66(6):4-12. (In Russ.) doi: https://doi.org/10.14341/probl12516Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: https://doi.org/10.1210/jc.2015-1710Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: https://doi.org/10.1210/jc.2015-1710Del Monte P, Bernasconi D, Bertolazzi L, et al. Increased 17 alpha-hydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect?. Clin Endocrinol (Oxf ). 1995;42(3):273-277. doi: https://doi.org/10.1111/j.1365-2265.1995.tb01875.xDel Monte P, Bernasconi D, Bertolazzi L, et al. Increased 17 alpha-hydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect?. Clin Endocrinol (Oxf ). 1995;42(3):273-277. doi: https://doi.org/10.1111/j.1365-2265.1995.tb01875.xJaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1992;74(3):685-689. doi: https://doi.org/10.1210/jcem.74.3.1311000Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1992;74(3):685-689. doi: https://doi.org/10.1210/jcem.74.3.1311000Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline [published correction appears in J Clin Endocrinol Metab. 2019 Jan 1;104(1):39-40]. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi: https://doi.org/10.1210/jc.2018-01865Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline [published correction appears in J Clin Endocrinol Metab. 2019 Jan 1;104(1):39-40]. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi: https://doi.org/10.1210/jc.2018-01865Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab. 2005;19(2):277-292. doi: https://doi.org/10.1016/j.beem.2004.09.002Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab. 2005;19(2):277-292. doi: https://doi.org/10.1016/j.beem.2004.09.002McCarthy CJ, McDermott S, Blake MA. Adrenal Imaging: Magnetic Resonance Imaging and Computed Tomography. Front Horm Res. 2016;45:55-69. doi: https://doi.org/10.1159/000442313McCarthy CJ, McDermott S, Blake MA. Adrenal Imaging: Magnetic Resonance Imaging and Computed Tomography. Front Horm Res. 2016;45:55-69. doi: https://doi.org/10.1159/000442313Warda MH, Shehata SM, Zaiton F. Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas. Clin Imaging. 2016;40(4):780-787. doi: https://doi.org/10.1016/j.clinimag.2016.02.006Warda MH, Shehata SM, Zaiton F. Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas. Clin Imaging. 2016;40(4):780-787. doi: https://doi.org/10.1016/j.clinimag.2016.02.006Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871-877. doi: https://doi.org/10.1210/jc.2004-1627Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871-877. doi: https://doi.org/10.1210/jc.2004-1627Dinnes J, Bancos I, Ferrante di Ruffano L, et al. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R51-R64. doi: https://doi.org/10.1530/EJE-16-0461Dinnes J, Bancos I, Ferrante di Ruffano L, et al. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R51-R64. doi: https://doi.org/10.1530/EJE-16-0461Sabet FA, Majdzadeh R, Mostafazadeh Davani B, Heidari K, Soltani A. Likelihood ratio of computed tomography characteristics for diagnosis of malignancy in adrenal incidentaloma: systematic review and meta-analysis. J Diabetes Metab Disord. 2016;15:12. Published 2016 Apr 21. doi: https://doi.org/10.1186/s40200-016-0224-zSabet FA, Majdzadeh R, Mostafazadeh Davani B, Heidari K, Soltani A. Likelihood ratio of computed tomography characteristics for diagnosis of malignancy in adrenal incidentaloma: systematic review and meta-analysis. J Diabetes Metab Disord. 2016;15:12. Published 2016 Apr 21. doi: https://doi.org/10.1186/s40200-016-0224-zTerzolo M, Reimondo G, Bovio S, Angeli A. Subclinical Cushing’s syndrome. Pituitary. 2004;7(4):217-223. doi: https://doi.org/10.1007/s11102-005-4024-6Terzolo M, Reimondo G, Bovio S, Angeli A. Subclinical Cushing’s syndrome. Pituitary. 2004;7(4):217-223. doi: https://doi.org/10.1007/s11102-005-4024-6Fan J, Tang J, Fang J, et al. Ultrasound imaging in the diagnosis of benign and suspicious adrenal lesions. Med Sci Monit. 2014;20:2132-2141. Published 2014 Nov 3. doi: https://doi.org/10.12659/MSM.890800Fan J, Tang J, Fang J, et al. Ultrasound imaging in the diagnosis of benign and suspicious adrenal lesions. Med Sci Monit. 2014;20:2132-2141. Published 2014 Nov 3. doi: https://doi.org/10.12659/MSM.890800Petersenn S, Richter PA, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415-422. doi: https://doi.org/10.1530/EJE-14-0916Petersenn S, Richter PA, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415-422. doi: https://doi.org/10.1530/EJE-14-0916Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies — a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. doi: https://doi.org/10.1967/s002449910202Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies — a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. doi: https://doi.org/10.1967/s002449910202Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. 2017;102(7):2465-2472. doi: https://doi.org/10.1210/jc.2017-00254Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. 2017;102(7):2465-2472. doi: https://doi.org/10.1210/jc.2017-00254Nakajo M, Jinguji M, Nakajo M, et al. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters. Abdom Radiol (NY). 2017;42(12):2882-2889. doi: https://doi.org/10.1007/s00261-017-1207-3Nakajo M, Jinguji M, Nakajo M, et al. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters. Abdom Radiol (NY). 2017;42(12):2882-2889. doi: https://doi.org/10.1007/s00261-017-1207-3Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. doi: https://doi.org/10.1259/bjr.20170520Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. doi: https://doi.org/10.1259/bjr.20170520Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-4767. doi: https://doi.org/10.1210/jc.2009-1248Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-4767. doi: https://doi.org/10.1210/jc.2009-1248Alencar GA, Fragoso MC, Yamaga LY, et al. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab. 2011;96(11):3300-3301. doi: https://doi.org/10.1210/jc.2011-1397Alencar GA, Fragoso MC, Yamaga LY, et al. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab. 2011;96(11):3300-3301. doi: https://doi.org/10.1210/jc.2011-1397Arellano RS, Harisinghani MG, Gervais DA, et al. Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol. 2003;32(1):3-10. doi: https://doi.org/10.1067/cdr.2003.120002Arellano RS, Harisinghani MG, Gervais DA, et al. Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol. 2003;32(1):3-10. doi: https://doi.org/10.1067/cdr.2003.120002Harisinghani MG, Maher MM, Hahn PF, et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol. 2002;57(10):898-901. doi: https://doi.org/10.1053/crad.2002.1054Harisinghani MG, Maher MM, Hahn PF, et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol. 2002;57(10):898-901. doi: https://doi.org/10.1053/crad.2002.1054Bancos I, Tamhane S, Shah M, et al. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R65-R80. doi: https://doi.org/10.1530/EJE-16-0297Bancos I, Tamhane S, Shah M, et al. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R65-R80. doi: https://doi.org/10.1530/EJE-16-0297Молашенко Н.В., Платонова Н.М., Бельцевич Д.Г., и др. Дифференциальная диагностика инциденталом надпочечников // Ожирение и метаболизм. — 2016. — Т. 13. — №.4 — С. 39-44. doi: 10.14341/OMET2016439-44Molashenko NV, Platonova NM, Beltsevich DG, et al. Diagnosis and differential diagnosis of adrenal incidentalomas. Obesity and metabolism. 2016;13(4):39-44. (In Russ.) doi: 10.14341/OMET2016439-44Anagnostis P, Efstathiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas — a single center experience and review of the literature. Exp Clin Endocrinol Diabetes. 2010;118(9):610-616. doi: https://doi.org/10.1055/s-0029-1237704Anagnostis P, Efstathiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas — a single center experience and review of the literature. Exp Clin Endocrinol Diabetes. 2010;118(9):610-616. doi: https://doi.org/10.1055/s-0029-1237704Yilmaz H, Tütüncü NB, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest. 2009;32(11):913-916. doi: https://doi.org/10.1007/BF03345772Yilmaz H, Tütüncü NB, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest. 2009;32(11):913-916. doi: https://doi.org/10.1007/BF03345772Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58(4):609-615. doi: https://doi.org/10.1016/j.eururo.2010.06.024Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58(4):609-615. doi: https://doi.org/10.1016/j.eururo.2010.06.024Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. Surg Endosc. 2013;27(11):4026-4032. doi: https://doi.org/10.1007/s00464-013-3034-0Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. Surg Endosc. 2013;27(11):4026-4032. doi: https://doi.org/10.1007/s00464-013-3034-0Donatini G, Caiazzo R, Do Cao C, et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol. 2014;21(1):284-291. doi: https://doi.org/10.1245/s10434-013-3164-6Donatini G, Caiazzo R, Do Cao C, et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol. 2014;21(1):284-291. doi: https://doi.org/10.1245/s10434-013-3164-6Fosså A, Røsok BI, Kazaryan AM, et al. Laparoscopic versus open surgery in stage I-III adrenocortical carcinoma -- a retrospective comparison of 32 patients. Acta Oncol. 2013;52(8):1771-1777. doi: https://doi.org/10.3109/0284186X.2013.765065Fosså A, Røsok BI, Kazaryan AM, et al. Laparoscopic versus open surgery in stage I-III adrenocortical carcinoma -- a retrospective comparison of 32 patients. Acta Oncol. 2013;52(8):1771-1777. doi: https://doi.org/10.3109/0284186X.2013.765065Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158-1164. doi: https://doi.org/10.1016/j.surg.2012.08.014Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158-1164. doi: https://doi.org/10.1016/j.surg.2012.08.014Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34(6):1380-1385. doi: https://doi.org/10.1007/s00268-010-0532-2Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34(6):1380-1385. doi: https://doi.org/10.1007/s00268-010-0532-2Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157. doi: https://doi.org/10.1016/j.surg.2012.08.024Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157. doi: https://doi.org/10.1016/j.surg.2012.08.024Mir MC, Klink JC, Guillotreau J, et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol. 2013;20(5):1456-1461. doi: https://doi.org/10.1245/s10434-012-2760-1Mir MC, Klink JC, Guillotreau J, et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol. 2013;20(5):1456-1461. doi: https://doi.org/10.1245/s10434-012-2760-1Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57(5):873-878. doi: https://doi.org/10.1016/j.eururo.2010.01.036Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57(5):873-878. doi: https://doi.org/10.1016/j.eururo.2010.01.036Langenhuijsen J, Birtle A, Klatte T, et al. Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature [published correction appears in Eur Urol Focus. 2018 Apr;4(3):461]. Eur Urol Focus. 2016;1(3):241-250. doi: https://doi.org/10.1016/j.euf.2015.12.001Langenhuijsen J, Birtle A, Klatte T, et al. Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature [published correction appears in Eur Urol Focus. 2018 Apr;4(3):461]. Eur Urol Focus. 2016;1(3):241-250. doi: https://doi.org/10.1016/j.euf.2015.12.001Morelli V, Minelli L, Eller-Vainicher C, et al. Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism. J Endocrinol Invest. 2018;41(4):485-493. doi: https://doi.org/10.1007/s40618-017-0788-6Morelli V, Minelli L, Eller-Vainicher C, et al. Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism. J Endocrinol Invest. 2018;41(4):485-493. doi: https://doi.org/10.1007/s40618-017-0788-6Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral Adrenalectomy as a First-Line Treatment of Cushing’s Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab. 2015;100(12):4417-4424. doi: https://doi.org/10.1210/jc.2015-2662Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral Adrenalectomy as a First-Line Treatment of Cushing’s Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab. 2015;100(12):4417-4424. doi: https://doi.org/10.1210/jc.2015-2662Osswald A, Quinkler M, Di Dalmazi G, et al. Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. J Clin Endocrinol Metab. 2019;104(7):2985-2993. doi: https://doi.org/10.1210/jc.2018-02204Osswald A, Quinkler M, Di Dalmazi G, et al. Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. J Clin Endocrinol Metab. 2019;104(7):2985-2993. doi: https://doi.org/10.1210/jc.2018-02204Sheikh-Ahmad M, Dickstein G, Matter I, et al. Unilateral Adrenalectomy for Primary Bilateral Macronodular Adrenal Hyperplasia: Analysis of 71 Cases. Exp Clin Endocrinol Diabetes. 2020;128(12):827-834. doi: https://doi.org/10.1055/a-0998-7884Sheikh-Ahmad M, Dickstein G, Matter I, et al. Unilateral Adrenalectomy for Primary Bilateral Macronodular Adrenal Hyperplasia: Analysis of 71 Cases. Exp Clin Endocrinol Diabetes. 2020;128(12):827-834. doi: https://doi.org/10.1055/a-0998-7884Xu Y, Rui W, Qi Y, et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg. 2013;37(7):1626-1632. doi: https://doi.org/10.1007/s00268-013-2059-9Xu Y, Rui W, Qi Y, et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg. 2013;37(7):1626-1632. doi: https://doi.org/10.1007/s00268-013-2059-9Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005;92(6):1104-1109. doi: https://doi.org/10.1038/sj.bjc.6602459Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005;92(6):1104-1109. doi: https://doi.org/10.1038/sj.bjc.6602459Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999;84(2):520-526. doi: https://doi.org/10.1210/jcem.84.2.5444Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999;84(2):520-526. doi: https://doi.org/10.1210/jcem.84.2.5444Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010;162(4):779-785. doi: https://doi.org/10.1530/EJE-09-0957Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010;162(4):779-785. doi: https://doi.org/10.1530/EJE-09-0957Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-285. doi: https://doi.org/10.1530/eje.0.1490273Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-285. doi: https://doi.org/10.1530/eje.0.1490273Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754-773. doi: https://doi.org/10.1016/j.jacr.2010.06.013Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754-773. doi: https://doi.org/10.1016/j.jacr.2010.06.013Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi: https://doi.org/10.1016/j.ejca.2008.10.026Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi: https://doi.org/10.1016/j.ejca.2008.10.026Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553-1562. doi: https://doi.org/10.1210/jc.2008-0139Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553-1562. doi: https://doi.org/10.1210/jc.2008-0139

The authors declare that there are no conflicts of interest present.